Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

InMed Pharmaceuticals (INM) EBIAT (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of EBIAT data on record, last reported at -$2.1 million in Q4 2025.

  • For Q4 2025, EBIAT rose 19.49% year-over-year to -$2.1 million; the TTM value through Dec 2025 reached -$7.7 million, up 2.88%, while the annual FY2025 figure was -$8.2 million, 6.0% down from the prior year.
  • EBIAT reached -$2.1 million in Q4 2025 per INM's latest filing, down from -$1.7 million in the prior quarter.
  • Across five years, EBIAT topped out at -$300000.0 in Q2 2023 and bottomed at -$7.9 million in Q2 2022.
  • Average EBIAT over 5 years is -$2.6 million, with a median of -$2.1 million recorded in 2022.
  • Peak YoY movement for EBIAT: skyrocketed 96.19% in 2023, then crashed 554.04% in 2024.
  • A 5-year view of EBIAT shows it stood at -$4.3 million in 2021, then surged by 50.94% to -$2.1 million in 2022, then grew by 29.65% to -$1.5 million in 2023, then plummeted by 74.2% to -$2.6 million in 2024, then rose by 19.49% to -$2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIAT were -$2.1 million in Q4 2025, -$1.7 million in Q3 2025, and -$1.8 million in Q2 2025.